RxDoctor Payments Data

Rebecca Szewczak, DO

Family Medicine · Enid, OKNPI 1598039679

Payments from drug & device makers

$1,985in general payments, 2019–2025

Across 124 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$411
  • AbbVie$377
  • Novo Nordisk$183
  • Merck$143
  • GSK$123
  • Boehringer Ingelheim$100
  • plus $647 from 18 others

What the payments were for

  • Food & beverage$1,95398%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,985 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$59,420
Medicare patients
177
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$55,600
TrulicityDulaglutide28$32,125
EliquisApixaban35$29,411
FarxigaDapagliflozin Propanediol16$18,790
JanuviaSitagliptin Phosphate12$18,032
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$14,303
MounjaroTirzepatide11$10,785
XareltoRivaroxaban11$10,164
Tresiba Flextouch U-200Insulin Degludec14$8,790
Repatha SyringeEvolocumab11$5,914
BrilintaTicagrelor13$5,757
DayvigoLemborexant11$3,566
Humalog Kwikpen U-100Insulin Lispro24$3,014
Levothyroxine Sodium253$2,634
Rosuvastatin Calcium116$2,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$183$55,60049 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$72$43,79757 claims
PfizerEliquis$45$29,41135 claims
AstraZenecaFarxiga, Brilinta$411$24,54729 claims
MerckJanuvia$143$18,03212 claims
Johnson & JohnsonXarelto$55$10,16411 claims
Eisai Inc.Dayvigo$17$3,56611 claims
AbbVieSynthroid$377$59311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →